Bibliography: library/10665-360869
The reference for library/10665-360869 (who-iris) and any references extracted from it. library · All references.
Export these 43 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD
✍ + Add reference (standalone node)
43 shown
-
World Health Organization (2022). Guidelines on long-acting injectable cabotegravir for HIV prevention. World Health Organization.
10665-360869· catalogue · link · repository record · ISBN 9789240054097 (electronic version) · source:catalogue/records/10665-360869.dc.json· held:library/10665-360869
export: BibTeX · RIS · CSL-JSON · DC XML -
Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/186275, accessed 18 May 2022).
· extracted · link · source:references/10665-360869.sec-036.1.jsonGuideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/186275, accessed 18 May 2022).
- Issued
- 2015
- Type
- document
- Accessed
- 18 May 2022
- As printed
- Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/186275, accessed 18 May 2022).
Sources
- apps.who.int/iris/handle/10665/186275 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.1 - provenance: extracted
- read from
references/10665-360869.sec-036.1.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340190, accessed 18 May 2022).
· extracted · link · source:references/10665-360869.sec-036.2.json· held:library/10665-340190Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340190, accessed 18 May 2022).
- Issued
- 2021
- Type
- document
- Accessed
- 18 May 2022
- As printed
- Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340190, accessed 18 May 2022).
Sources
- apps.who.int/iris/handle/10665/340190 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.2 - provenance: extracted
- read from
references/10665-360869.sec-036.2.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md - library copy:
library/10665-340190
-
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 18 May 2022).
· extracted · link · source:references/10665-360869.sec-036.3.jsonConsolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 18 May 2022).
- Issued
- 2021
- Type
- document
- Accessed
- 18 May 2022
- As printed
- Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 18 May 2022).
Sources
- apps.who.int/iris/handle/10665/342899 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.3 - provenance: extracted
- read from
references/10665-360869.sec-036.3.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
2021 UNAIDS Global AIDS Update — Confronting inequalities — Lessons for pandemic responses from 40 years of AIDS. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, accessed 27 June 2022).
· extracted · link · source:references/10665-360869.sec-036.4.json2021 UNAIDS Global AIDS Update — Confronting inequalities — Lessons for pandemic responses from 40 years of AIDS. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, accessed 27 June 2022).
- Issued
- 2021
- Type
- document
- Accessed
- 27 June 2022
- As printed
- 2021 UNAIDS Global AIDS Update — Confronting inequalities — Lessons for pandemic responses from 40 years of AIDS. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, accessed 27 June 2022).
Sources
In the knowledge graph
- IRI
references/10665-360869.sec-036.4 - provenance: extracted
- read from
references/10665-360869.sec-036.4.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
United Nations General Assembly. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf, accessed 27 June 2022).
· extracted · link · source:references/10665-360869.sec-036.5.jsonUnited Nations General Assembly. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf, accessed 27 June 2022).
- Issued
- 2021
- Type
- document
- Accessed
- 27 June 2022
- As printed
- United Nations General Assembly. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf, accessed 27 June 2022).
Sources
- www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.5 - provenance: extracted
- read from
references/10665-360869.sec-036.5.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Schaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8:e502-e10.
· extracted · source:references/10665-360869.sec-036.6.jsonSchaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8:e502-e10.
- Issued
- 2021
- Type
- article-journal
- As printed
- Schaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8:e502-e10.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.6 - provenance: extracted
- read from
references/10665-360869.sec-036.6.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31:545-53.
· extracted · source:references/10665-360869.sec-036.7.jsonDubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31:545-53.
- Issued
- 2019
- Type
- article-journal
- As printed
- Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31:545-53.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.7 - provenance: extracted
- read from
references/10665-360869.sec-036.7.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Kuteesa MO, Quaife M, Biraro S, Katumba KR, Seeley J, Kamali A et al. Acceptability and predictors of uptake of anti-retroviral pre-exposure prophylaxis (PrEP) among fishing communities in Uganda: a cross-sectional discrete choice experiment survey. AIDS Behav. 2019;23:2674-86.
· extracted · source:references/10665-360869.sec-036.8.jsonKuteesa MO, Quaife M, Biraro S, Katumba KR, Seeley J, Kamali A et al. Acceptability and predictors of uptake of anti-retroviral pre-exposure prophylaxis (PrEP) among fishing communities in Uganda: a cross-sectional discrete choice experiment survey. AIDS Behav. 2019;23:2674-86.
- Issued
- 2019
- Type
- article-journal
- As printed
- Kuteesa MO, Quaife M, Biraro S, Katumba KR, Seeley J, Kamali A et al. Acceptability and predictors of uptake of anti-retroviral pre-exposure prophylaxis (PrEP) among fishing communities in Uganda: a cross-sectional discrete choice experiment survey. AIDS Behav. 2019;23:2674-86.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.8 - provenance: extracted
- read from
references/10665-360869.sec-036.8.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S et al. Preferences for long‐acting Pre‐Exposure prophylaxis (PreP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020;23:e25528.
· extracted · source:references/10665-360869.sec-036.9.jsonMinnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S et al. Preferences for long‐acting Pre‐Exposure prophylaxis (PreP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020;23:e25528.
- Issued
- 2020
- Type
- article-journal
- As printed
- Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S et al. Preferences for long‐acting Pre‐Exposure prophylaxis (PreP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020;23:e25528.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.9 - provenance: extracted
- read from
references/10665-360869.sec-036.9.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Minnis AM, Browne EN, Boeri M, Agot K, Van Der Straten A, Ahmed K et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80:394.
· extracted · source:references/10665-360869.sec-036.10.jsonMinnis AM, Browne EN, Boeri M, Agot K, Van Der Straten A, Ahmed K et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80:394.
- Issued
- 2019
- Type
- article-journal
- As printed
- Minnis AM, Browne EN, Boeri M, Agot K, Van Der Straten A, Ahmed K et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80:394.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.10 - provenance: extracted
- read from
references/10665-360869.sec-036.10.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38:120-33.
· extracted · source:references/10665-360869.sec-036.11.jsonQuaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38:120-33.
- Issued
- 2018
- Type
- article-journal
- As printed
- Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38:120-33.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.11 - provenance: extracted
- read from
references/10665-360869.sec-036.11.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Vickerman P, Quaife M, Kilbourne-Brook M, Mvundura M, Eakle R, Terris-Prestholt F. HIV prevention is not all about HIV–using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. BMC Infect Dis. 2020;20:1-11.
· extracted · source:references/10665-360869.sec-036.12.jsonVickerman P, Quaife M, Kilbourne-Brook M, Mvundura M, Eakle R, Terris-Prestholt F. HIV prevention is not all about HIV–using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. BMC Infect Dis. 2020;20:1-11.
- Issued
- 2020
- Type
- article-journal
- As printed
- Vickerman P, Quaife M, Kilbourne-Brook M, Mvundura M, Eakle R, Terris-Prestholt F. HIV prevention is not all about HIV–using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. BMC Infect Dis. 2020;20:1-11.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.12 - provenance: extracted
- read from
references/10665-360869.sec-036.12.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779-89. Erratum in: Lancet. 2022 May 7;399(10337):1778. PMID: 35378077.
· extracted · source:references/10665-360869.sec-036.13.jsonDelany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779-89. Erratum in: Lancet. 2022 May 7;399(10337):1778. PMID: 35378077.
- Issued
- 2022
- Type
- article-journal
- As printed
- Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779-89. Erratum in: Lancet. 2022 May 7;399(10337):1778. PMID: 35378077.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.13 - provenance: extracted
- read from
references/10665-360869.sec-036.13.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
· extracted · source:references/10665-360869.sec-036.14.jsonLandovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
- Issued
- 2021
- Type
- article-journal
- As printed
- Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.14 - provenance: extracted
- read from
references/10665-360869.sec-036.14.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
FDA approves first injectable treatment for HIV pre-exposure prevention [press release]. Washington (DC): U.S. Food and Drug Administration; 2021 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention, accessed 27 June 2022).
· extracted · link · source:references/10665-360869.sec-036.15.jsonFDA approves first injectable treatment for HIV pre-exposure prevention [press release]. Washington (DC): U.S. Food and Drug Administration; 2021 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention, accessed 27 June 2022).
- Issued
- 2021
- Type
- document
- Accessed
- 27 June 2022
- As printed
- FDA approves first injectable treatment for HIV pre-exposure prevention [press release]. Washington (DC): U.S. Food and Drug Administration; 2021 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention, accessed 27 June 2022).
Sources
In the knowledge graph
- IRI
references/10665-360869.sec-036.15 - provenance: extracted
- read from
references/10665-360869.sec-036.15.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
WHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
· extracted · link · source:references/10665-360869.sec-036.16.jsonWHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
- Issued
- 2014
- Type
- document
- Accessed
- 17 February 2022
- As printed
- WHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
Sources
- apps.who.int/iris/handle/10665/145714 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.16 - provenance: extracted
- read from
references/10665-360869.sec-036.16.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A et al. Going from evidence to recommendations. BMJ. 2008;336:1049-51.
· extracted · source:references/10665-360869.sec-036.17.jsonGuyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A et al. Going from evidence to recommendations. BMJ. 2008;336:1049-51.
- Issued
- 2008
- Type
- article-journal
- As printed
- Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A et al. Going from evidence to recommendations. BMJ. 2008;336:1049-51.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.17 - provenance: extracted
- read from
references/10665-360869.sec-036.17.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Ahluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898.
· extracted · source:references/10665-360869.sec-036.18.jsonAhluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898.
- Issued
- 2022
- Type
- article-journal
- As printed
- Ahluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.18 - provenance: extracted
- read from
references/10665-360869.sec-036.18.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
HIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
· extracted · source:references/10665-360869.sec-036.19.jsonHIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
- Type
- document
- As printed
- HIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.19 - provenance: extracted
- read from
references/10665-360869.sec-036.19.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
· extracted · source:references/10665-360869.sec-036.20.jsonLandovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
- Issued
- 2018
- Type
- article-journal
- As printed
- Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.20 - provenance: extracted
- read from
references/10665-360869.sec-036.20.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e40.
· extracted · source:references/10665-360869.sec-036.21.jsonMarkowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e40.
- Issued
- 2017
- Type
- article-journal
- As printed
- Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e40.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.21 - provenance: extracted
- read from
references/10665-360869.sec-036.21.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Landovitz R, Donnell D, Kallas E, Magnus M, Marzinke M. Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs. TDF/FTC For PrEP. Conference on Retroviruses and Opportunistic Infections (CROI); virtual, 2022.
· extracted · source:references/10665-360869.sec-036.22.jsonLandovitz R, Donnell D, Kallas E, Magnus M, Marzinke M. Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs. TDF/FTC For PrEP. Conference on Retroviruses and Opportunistic Infections (CROI); virtual, 2022.
- Issued
- 2022
- Type
- document
- As printed
- Landovitz R, Donnell D, Kallas E, Magnus M, Marzinke M. Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs. TDF/FTC For PrEP. Conference on Retroviruses and Opportunistic Infections (CROI); virtual, 2022.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.22 - provenance: extracted
- read from
references/10665-360869.sec-036.22.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Dimitrov D. Population impact of expanding PrEP coverage by offering long-acting injectable cabotegravir as PrEP: Model comparison analysis. Unpublished.
· extracted · source:references/10665-360869.sec-036.23.jsonDimitrov D. Population impact of expanding PrEP coverage by offering long-acting injectable cabotegravir as PrEP: Model comparison analysis. Unpublished.
- Type
- document
- As printed
- Dimitrov D. Population impact of expanding PrEP coverage by offering long-acting injectable cabotegravir as PrEP: Model comparison analysis. Unpublished.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.23 - provenance: extracted
- read from
references/10665-360869.sec-036.23.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224:1581-92.
· extracted · source:references/10665-360869.sec-036.24.jsonMarzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224:1581-92.
- Issued
- 2021
- Type
- article-journal
- As printed
- Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224:1581-92.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.24 - provenance: extracted
- read from
references/10665-360869.sec-036.24.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
HIV drug resistance database [website]. Menlo Park (CA): Stanford University; 2022 (https://hivdb.stanford.edu/, accessed 27 June 2022).
· extracted · link · source:references/10665-360869.sec-036.25.jsonHIV drug resistance database [website]. Menlo Park (CA): Stanford University; 2022 (https://hivdb.stanford.edu/, accessed 27 June 2022).
- Issued
- 2022
- Type
- document
- Accessed
- 27 June 2022
- As printed
- HIV drug resistance database [website]. Menlo Park (CA): Stanford University; 2022 (https://hivdb.stanford.edu/, accessed 27 June 2022).
Sources
- hivdb.stanford.edu/ (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.25 - provenance: extracted
- read from
references/10665-360869.sec-036.25.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Meyer-Rath G. Cost-effectiveness modelling. Unpublished.
· extracted · source:references/10665-360869.sec-036.26.jsonMeyer-Rath G. Cost-effectiveness modelling. Unpublished.
- Type
- document
- As printed
- Meyer-Rath G. Cost-effectiveness modelling. Unpublished.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.26 - provenance: extracted
- read from
references/10665-360869.sec-036.26.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA et al. Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020;85:93. Guidelines on long-acting injectable cabotegravir for HIV prevention
· extracted · source:references/10665-360869.sec-036.27.jsonBlair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA et al. Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020;85:93. Guidelines on long-acting injectable cabotegravir for HIV prevention
- Issued
- 2020
- Type
- article-journal
- As printed
- Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA et al. Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020;85:93. Guidelines on long-acting injectable cabotegravir for HIV prevention
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.27 - provenance: extracted
- read from
references/10665-360869.sec-036.27.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E et al. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Rev Infect Dis. 2016;63:539-47.
· extracted · source:references/10665-360869.sec-036.28.jsonGlaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E et al. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Rev Infect Dis. 2016;63:539-47.
- Issued
- 2016
- Type
- article-journal
- As printed
- Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E et al. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Rev Infect Dis. 2016;63:539-47.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.28 - provenance: extracted
- read from
references/10665-360869.sec-036.28.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Quaife M, Terris‐Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne‐Brook M, Mvundura M et al. The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018;21:e25064.
· extracted · source:references/10665-360869.sec-036.29.jsonQuaife M, Terris‐Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne‐Brook M, Mvundura M et al. The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018;21:e25064.
- Issued
- 2018
- Type
- article-journal
- As printed
- Quaife M, Terris‐Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne‐Brook M, Mvundura M et al. The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018;21:e25064.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.29 - provenance: extracted
- read from
references/10665-360869.sec-036.29.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Smith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. J Infect Dis. 2021;224:1179-86.
· extracted · source:references/10665-360869.sec-036.30.jsonSmith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. J Infect Dis. 2021;224:1179-86.
- Issued
- 2021
- Type
- article-journal
- As printed
- Smith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. J Infect Dis. 2021;224:1179-86.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.30 - provenance: extracted
- read from
references/10665-360869.sec-036.30.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019;22:e25427.
· extracted · source:references/10665-360869.sec-036.31.jsonvan Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019;22:e25427.
- Issued
- 2019
- Type
- article-journal
- As printed
- van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019;22:e25427.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.31 - provenance: extracted
- read from
references/10665-360869.sec-036.31.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Vogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. J Acquir Immune Defic Syndr. 2020;84:173-81.
· extracted · source:references/10665-360869.sec-036.32.jsonVogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. J Acquir Immune Defic Syndr. 2020;84:173-81.
- Issued
- 2020
- Type
- article-journal
- As printed
- Vogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. J Acquir Immune Defic Syndr. 2020;84:173-81.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.32 - provenance: extracted
- read from
references/10665-360869.sec-036.32.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Walensky RP, Jacobsen MM, Bekker L-G, Parker RA, Wood R, Resch SC et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213:1523-31.
· extracted · source:references/10665-360869.sec-036.33.jsonWalensky RP, Jacobsen MM, Bekker L-G, Parker RA, Wood R, Resch SC et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213:1523-31.
- Issued
- 2016
- Type
- article-journal
- As printed
- Walensky RP, Jacobsen MM, Bekker L-G, Parker RA, Wood R, Resch SC et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213:1523-31.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.33 - provenance: extracted
- read from
references/10665-360869.sec-036.33.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175:479-89.
· extracted · source:references/10665-360869.sec-036.34.jsonNeilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175:479-89.
- Issued
- 2022
- Type
- article-journal
- As printed
- Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175:479-89.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.34 - provenance: extracted
- read from
references/10665-360869.sec-036.34.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394:303-13.
· extracted · source:references/10665-360869.sec-036.35.jsonAhmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394:303-13.
- Issued
- 2019
- Type
- article-journal
- As printed
- Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394:303-13.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.35 - provenance: extracted
- read from
references/10665-360869.sec-036.35.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Luo R, Fong Y, Boeras D, Jani I, Vojnov L. The clinical impact of point-of-care infant diagnosis for HIV: a systematic review and meta-analysis. Lancet. 2022. In review.
· extracted · source:references/10665-360869.sec-036.36.jsonLuo R, Fong Y, Boeras D, Jani I, Vojnov L. The clinical impact of point-of-care infant diagnosis for HIV: a systematic review and meta-analysis. Lancet. 2022. In review.
- Issued
- 2022
- Type
- document
- As printed
- Luo R, Fong Y, Boeras D, Jani I, Vojnov L. The clinical impact of point-of-care infant diagnosis for HIV: a systematic review and meta-analysis. Lancet. 2022. In review.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.36 - provenance: extracted
- read from
references/10665-360869.sec-036.36.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10:1263.
· extracted · source:references/10665-360869.sec-036.37.jsonOtto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10:1263.
- Issued
- 2021
- Type
- article-journal
- As printed
- Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10:1263.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-036.37 - provenance: extracted
- read from
references/10665-360869.sec-036.37.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
National Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent males - a sub-study of HPTN 083. Identifier: NCT04692077. (2020, February – 2023, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04692077, accessed 18 May 2022).
· extracted · link · source:references/10665-360869.sec-036.38.jsonNational Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent males - a sub-study of HPTN 083. Identifier: NCT04692077. (2020, February – 2023, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04692077, accessed 18 May 2022).
- Issued
- 2020
- Type
- document
- Accessed
- 18 May 2022
- As printed
- National Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent males - a sub-study of HPTN 083. Identifier: NCT04692077. (2020, February – 2023, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04692077, accessed 18 May 2022).
Sources
- www.clinicaltrials.gov/ct2/show/NCT04692077 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.38 - provenance: extracted
- read from
references/10665-360869.sec-036.38.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
National Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent females - a sub-study of HPTN 084. Identifier: NCT04824131. (2020, November – 2024, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04824131, accessed 18 May 2022).
· extracted · link · source:references/10665-360869.sec-036.39.jsonNational Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent females - a sub-study of HPTN 084. Identifier: NCT04824131. (2020, November – 2024, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04824131, accessed 18 May 2022).
- Issued
- 2020
- Type
- document
- Accessed
- 18 May 2022
- As printed
- National Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent females - a sub-study of HPTN 084. Identifier: NCT04824131. (2020, November – 2024, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04824131, accessed 18 May 2022).
Sources
- www.clinicaltrials.gov/ct2/show/NCT04824131 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-036.39 - provenance: extracted
- read from
references/10665-360869.sec-036.39.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-036-references.md
-
WHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
· extracted · link · source:references/10665-360869.sec-037.1.jsonWHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
- Issued
- 2014
- Type
- document
- Accessed
- 17 February 2022
- As printed
- WHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
Sources
- apps.who.int/iris/handle/10665/145714 (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-037.1 - provenance: extracted
- read from
references/10665-360869.sec-037.1.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-037-annex-1-process-for-developing-the-guidelines.md
-
HIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
· extracted · source:references/10665-360869.sec-037.2.jsonHIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
- Type
- document
- As printed
- HIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
Sources
No link to the work is recorded for this reference.
In the knowledge graph
- IRI
references/10665-360869.sec-037.2 - provenance: extracted
- read from
references/10665-360869.sec-037.2.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-037-annex-1-process-for-developing-the-guidelines.md
-
Ahluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898. For more information, contact: World Health Organization Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes 20, avenue Appia 1211 Geneva 27 Switzerland Email: hiv-aids@who.int www.who.int/hiv
· extracted · link · source:references/10665-360869.sec-037.3.jsonAhluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898. For more information, contact: World Health Organization Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes 20, avenue Appia 1211 Geneva 27 Switzerland Email: hiv-aids@who.int www.who.int/hiv
- Issued
- 2022
- Type
- article-journal
- As printed
- Ahluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898. For more information, contact: World Health Organization Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes 20, avenue Appia 1211 Geneva 27 Switzerland Email: hiv-aids@who.int www.who.int/hiv
Sources
- www.who.int/hiv (canonical)
In the knowledge graph
- IRI
references/10665-360869.sec-037.3 - provenance: extracted
- read from
references/10665-360869.sec-037.3.json(who-iris, sub-graph who-iris-references) - derived from
library/10665-360869/sections/sec-037-annex-1-process-for-developing-the-guidelines.md